nd
uncertainties in MedQuist's subsequent filings with the Securities and
Exchange Commission.
MedQuist Inc. and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share amounts)
Unaudited
Three months ended
March 31,
2008 2007
Net revenues $83,725 $89,066
Operating costs and expenses:
Cost of revenues 61,258 68,345
Selling, general and
administrative 13,095 14,693
Research and development 4,119 3,442
Depreciation 2,928 2,539
Amortization of intangible assets 1,361 1,346
Cost of investigation and legal
proceedings, net 6,398 1,741
Restructuring charges - 256
Total operating costs and expenses 89,159 92,362
Operating loss (5,434) (3,296)
Equity in income of affiliated company 16 260
Other income 438 -
Interest income, net 1,288 2,102
Loss before income taxes (3,692) (934)
Income tax provision 725 952
Net loss $(4,417) $(1,886)
Net loss per share:
Basic
'/>"/>
SOURCE MedQuist Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
QLT reports initial proof of concept data for punctal plug delivery technology2.
Neurobiological Technologies Reports Third Quarter Financial Results3.
Bionovo Reports First Quarter 2008 Financial Results4.
WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting5.
Cardium Reports on First Quarter 2008 Highlights and Financial Results6.
Novavax Reports First Quarter 2008 Financial Results7.
Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance8.
Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results9.
Pharmos Corporation Reports 2008 First Quarter Results10.
Halozyme Therapeutics Reports 2008 First Quarter Financial Results11.
Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008